EXHIBIT 99.1

JOINT FILING AGREEMENT

The undersigned hereby agree that the Statement on Schedule 13G/A filed herewith (and any amendments thereto), relating to the common stock of Prevail Therapeutics Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the undersigned.

This Agreement may be executed in counterparts and each of such counterparts taken together shall constitute one and the same instrument.

Dated this 16^th day of February, 2021.

CITADEL SECURITIES LLC

CITADEL ADVISORS LLC

By:	/s/ Guy Miller		By:	/s/ Gregory Johnson
	Guy Miller, Authorized Signatory			Gregory Johnson, Authorized Signatory

CALC IV LP

CITADEL ADVISORS HOLDINGS LP

By:	/s/ Guy Miller		By:	/s/ Gregory Johnson
	Guy Miller, Authorized Signatory			Gregory Johnson, Authorized Signatory

CITADEL SECURITIES GP LLC

CITADEL GP LLC

By:	/s/ Guy Miller		By:	/s/ Gregory Johnson
	Guy Miller, Authorized Signatory			Gregory Johnson, Authorized Signatory

KENNETH GRIFFIN

	By:	/s/ Gregory Johnson
		Gregory Johnson, attorney-in-fact^*

^* Gregory Johnson is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein. The power of attorney was filed as an attachment to a filing by Citadel Advisors LLC on Schedule 13G for Jaws Acquisition Corp. on February 1, 2021.

Prevail Therapeutics Inc. SC 13G/A